A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Read more about A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Read more about Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Read more about Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Read more about A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Read more about Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Read more about A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention Read more about A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Read more about Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine Read more about A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Read more about ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19